ZetrOZ Systems Reports Wearable Ultrasound Device, SAM, Receives Expanded FDA Re-Approval: Positioning the Company for Market Growth in 2021

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

December 29, 2020

ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound, an FDA-cleared bio regenerative medical device, is the global leader in development of SAM technologies.

With its reapproval for expanded use in 2020, the use of SAM ultrasound technology in both professional and at-home applications is expected to increase market growth significantly over the next several years.

“The benefits of SAM are growing clearer by the day as more research-based evidence becomes available supporting SAM’s ability to provide healing relief without surgery,” according to Dr. George Lewis, Founder and CEO of ZetrOZ. “More professional athletic organizations and sports medicine doctors are taking notice, and we hope that more people will come to learn about the deep healing relief that SAM technology can provide.”

SAM technology is backed by tens of millions of dollars from the National Institutes of Health (NIH) and Department of Defense (DoD) for its ability to treat pain without surgery or opioids. The use of SAM is being integrated into clinical training with plans to expand into commercial insurance markets to treat patients; over 300,000 patients have been treated across government agencies, including Veterans Affairs, DoD, and Department of Labor (DoL), and the private sector.

Multiple studies are always underway to increase the knowledge of SAM in sports medicine, pain management, and rheumatology. In addition to research on SAM products, ZetrOZ is developing a pipeline of additional bioelectronic devices to improve healthcare and society. ZetrOZ has a vision to help 100 Million patients suffering from chronic pain and soft-tissue injuries.



Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.